{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T23:53:25Z","timestamp":1772668405703,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shijiazhuang Science and Technology Plan Project","award":["241200193A"],"award-info":[{"award-number":["241200193A"]}]},{"name":"Shijiazhuang Science and Technology Plan Project","award":["241200193A"],"award-info":[{"award-number":["241200193A"]}]},{"name":"Shijiazhuang Science and Technology Plan Project","award":["241200193A"],"award-info":[{"award-number":["241200193A"]}]},{"name":"Shijiazhuang Science and Technology Plan Project","award":["241200193A"],"award-info":[{"award-number":["241200193A"]}]},{"name":"S&T Program of Hebei (the Central Guiding Local Science and Technology Development Fund","award":["226Z7724G"],"award-info":[{"award-number":["226Z7724G"]}]},{"name":"S&T Program of Hebei (the Central Guiding Local Science and Technology Development Fund","award":["226Z7724G"],"award-info":[{"award-number":["226Z7724G"]}]},{"name":"S&T Program of Hebei (the Central Guiding Local Science and Technology Development Fund","award":["226Z7724G"],"award-info":[{"award-number":["226Z7724G"]}]},{"name":"S&T Program of Hebei (the Central Guiding Local Science and Technology Development Fund","award":["226Z7724G"],"award-info":[{"award-number":["226Z7724G"]}]},{"name":"S&T Program of Hebei (the Central Guiding Local Science and Technology Development Fund","award":["226Z7724G"],"award-info":[{"award-number":["226Z7724G"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study aimed to establish a technical process for detecting nicotinic acetylcholine receptor (nAChR) antibodies using the transfected cell method and evaluate its application in the serological diagnosis of myasthenia gravis (MG), thereby enhancing diagnostic efficiency. Cell transfection technology was used to introduce various nAChR subunit combinations into HEK293 cells for antibody detection. Indirect immunofluorescence (IIF) was utilized to test nAChR antibodies in serum samples from 85 MG patients, and the results were compared for consistency with those of enzyme-linked immunosorbent assay (ELISA).The combination of fetal and adult AChR subunits in transfected cells exhibited the highest sensitivity for detecting serum antibodies in patients with MG. The prepared cell slides demonstrated excellent consistency with the ELISA kit results for 85 MG patients, yielding a Kappa value of 0.769, indicating excellent agreement between the two methods. Co-transfection of multiple AChR subunits successfully generated a cell expressing clustered nAChRs, establishing a highly sensitive detection technique for nAChR antibodies. This technique is invaluable for serological detection of patients with MG, facilitating early disease detection, condition assessment, and therapeutic guidance.<\/jats:p>","DOI":"10.1038\/s41598-026-38414-w","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:14:38Z","timestamp":1770707678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Application analysis of transfected cell method for detecting AChR antibodies in MG patients"],"prefix":"10.1038","volume":"16","author":[{"given":"Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenmin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaijuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longlong","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaxin","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanting","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"issue":"1","key":"38414_CR1","first-page":"6","volume":"27","author":"H Zhang","year":"2020","unstructured":"Zhang, H. & Wen, J. X. Advances in the diagnosis and treatment of myasthenia gravis. Chin. J. Neuroimmunol. Neurol. 27(1), 6\u20138 (2020).","journal-title":"Chin. J. Neuroimmunol. Neurol."},{"key":"38414_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596981","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis, K. & Tzartos, S. J. Myasthenia gravis: Autoantibody specificities and their role in MG management. Front. Neurol. 11, 596981 (2020).","journal-title":"Front. Neurol."},{"issue":"5","key":"38414_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00415-020-10342-3","volume":"268","author":"G Monte","year":"2021","unstructured":"Monte, G. et al. Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?. J. Neurol. 268(5), 1803\u20131807 (2021).","journal-title":"J. Neurol."},{"issue":"6","key":"38414_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/14737159.2021.1927715","volume":"21","author":"M Gastaldi","year":"2021","unstructured":"Gastaldi, M. et al. Improving laboratory diagnostics in myasthenia gravis. Expert Rev. Mol. Diagn. 21(6), 579\u2013590 (2021).","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"1","key":"38414_CR5","first-page":"5","volume":"57","author":"KX Jiao","year":"2024","unstructured":"Jiao, K. X. & Zhao, Z. B. Progress in understanding pathogenic autoantibodies and diagnostic technology review in patients with myasthenia gravis. Chin. J. Neurol. 57(1), 5\u20139 (2024).","journal-title":"Chin. J. Neurol."},{"issue":"Pt7","key":"38414_CR6","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","volume":"131","author":"MI Leite","year":"2008","unstructured":"Leite, M. I. et al. IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis. Brain 131(Pt7), 1940\u20131952 (2008).","journal-title":"Brain"},{"issue":"8","key":"38414_CR7","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/archneurol.2012.437","volume":"69","author":"S Jacob","year":"2012","unstructured":"Jacob, S. et al. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch. Neurol. 69(8), 994\u20131001 (2012).","journal-title":"Arch. Neurol."},{"issue":"1","key":"38414_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/joim.12163","volume":"275","author":"MG Huijbers","year":"2014","unstructured":"Huijbers, M. G. et al. Pathogenic immune mechanisms at the neuromuscular synapse: The role of specific antibody-binding epitopes in myasthenia gravis. J. Intern. Med. 275(1), 12\u201326 (2014).","journal-title":"J. Intern. Med."},{"key":"38414_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108327","volume":"9","author":"G Kordas","year":"2014","unstructured":"Kordas, G., Lagoumintzis, G., Sideris, S., Poulas, K. & Tzartos, S. J. Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients. PLoS ONE 9, e108327 (2014).","journal-title":"PLoS ONE"},{"key":"38414_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1600-065X.1998.tb01190.x","volume":"163","author":"SJ Tzartos","year":"1998","unstructured":"Tzartos, S. J. et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol. Rev. 163, 89\u2013120 (1998).","journal-title":"Immunol. Rev."},{"key":"38414_CR11","doi-asserted-by":"publisher","first-page":"E36","DOI":"10.1002\/mus.27177","volume":"63","author":"V Zouvelou","year":"2021","unstructured":"Zouvelou, V., Michail, M., Belimezi, M. & Zisimopoulou, P. Subunit specificity of the acetylcholine receptor antibodies in double seropositive myasthenia gravis. Muscle Nerve 63, E36\u2013E37 (2021).","journal-title":"Muscle Nerve"},{"issue":"44","key":"38414_CR12","doi-asserted-by":"publisher","first-page":"13898","DOI":"10.1523\/JNEUROSCI.2833-09.2009","volume":"29","author":"J Luo","year":"2009","unstructured":"Luo, J. et al. Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J. Neurosci. 29(44), 13898\u201313908 (2009).","journal-title":"J. Neurosci."},{"key":"38414_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s12264-012-1256-0","volume":"28","author":"QG Shi","year":"2012","unstructured":"Shi, Q. G. et al. Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis. Neurosci Bull. 28, 469\u2013474 (2012).","journal-title":"Neurosci Bull."},{"issue":"Pt7","key":"38414_CR14","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","volume":"131","author":"MI Leite","year":"2008","unstructured":"Leite, M. I. et al. IgG1 antibodies to acetylcholine receptors in seronegative myasthenia gravis. Brain 131(Pt7), 1940\u20131952 (2008).","journal-title":"Brain"},{"issue":"3","key":"38414_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1113\/jphysiol.1995.sp021090","volume":"489","author":"CF Newland","year":"1995","unstructured":"Newland, C. F. et al. Functional and non-functional isoforms of the human muscle acetylcholine receptor. J. Physiol. 489(3), 767\u2013778 (1995).","journal-title":"J. Physiol."},{"key":"38414_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1196\/annals.1254.009","volume":"998","author":"CP Wanamaker","year":"2003","unstructured":"Wanamaker, C. P. et al. Regulation of nicotinic acetylcholine receptor assembly. Ann. N. Y. Acad. Sci. 998, 66\u201380 (2003).","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"44","key":"38414_CR17","doi-asserted-by":"publisher","first-page":"13898","DOI":"10.1523\/JNEUROSCI.2833-09.2009","volume":"29","author":"J Luo","year":"2009","unstructured":"Luo, J. et al. Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J. Neurosci. 29(44), 13898\u201313908 (2009).","journal-title":"J. Neurosci."},{"key":"38414_CR18","volume":"38","author":"Z Li","year":"2023","unstructured":"Li, Z. et al. A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: The SCREAM study. Lancet Reg. Health West. Pac. 38, 100846 (2023).","journal-title":"Lancet Reg. Health West. Pac."},{"key":"38414_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.666046","volume":"12","author":"Y Cai","year":"2021","unstructured":"Cai, Y. et al. A stable cell line expressing clustered AChR: A novel cell-based assay for anti-AChR antibody detection in myasthenia gravis. Front. Immunol. 12, 666046 (2021).","journal-title":"Front. Immunol."},{"key":"38414_CR20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3988\/jcn.2021.17.3.400","volume":"17","author":"MJ Kim","year":"2021","unstructured":"Kim, M. J. et al. Evaluating an in-house cell-based assay for detecting antibodies against muscle-specific tyrosine kinase in myasthenia gravis. J. Clin. Neurol. 17, 400\u2013408 (2021).","journal-title":"J. Clin. Neurol."},{"key":"38414_CR21","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.3390\/jcm12144781","volume":"12","author":"CM Gambino","year":"2023","unstructured":"Gambino, C. M. et al. Detection of antibodies against the acetylcholine receptor in patients with Yasthenia gravis: A comparison of two enzyme immunoassays and a fixed cell-based assay. J. Clin. Med. 12, 4781 (2023).","journal-title":"J. Clin. Med."},{"key":"38414_CR22","doi-asserted-by":"publisher","first-page":"1459423","DOI":"10.3389\/fimmu.2025.1459423","volume":"16","author":"JS Tzartos","year":"2025","unstructured":"Tzartos, J. S. et al. Efficiency of cell-based assays in detecting AChR antibodies in myasthenia gravis sera with low antibody concentrations as determined by radioimmunoprecipitation assay. Front. Immunol. 16, 1459423 (2025).","journal-title":"Front. Immunol."},{"key":"38414_CR23","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200038","volume":"10","author":"G Spagni","year":"2022","unstructured":"Spagni, G. et al. Comparison of fixed and live cell-based assay for the detection of AChR and MuSK antibodies in myasthenia gravis. Neurol. Neuroimmunol. Neuroinflamm. 10, e200038 (2022).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38414-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38414-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38414-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T23:01:46Z","timestamp":1772665306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38414-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38414"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38414-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"8130"}}